Manufacturing guide
Tablet Manufacturing Process for Supplements
Tablet manufacturing may use direct compression, dry granulation or wet granulation. The correct flow depends on material behaviour, product requirements and the controls needed at scale.
Short answer
Supplement tablets are commonly made by dispensing materials, preparing a blend or granules, lubricating where required, compressing, optionally coating, testing and packaging. Not every product uses every step.
Direct compression can move from blending to compression. Wet granulation adds liquid, granulation, drying and milling. Dry granulation adds compaction and milling without a liquid. The formulation's flow, compactability, uniformity and sensitivity determine which route is appropriate.
Evidence guide: Published evidence — supported by the linked technical source. · Development guidance — a practical way to frame or test the product, not a universal specification. · Manufacturer-specific — depends on the selected process, equipment and commercial arrangement. · Product-specific validation — must be demonstrated with the actual formula, process, pack and market.
Three common process routes
| Route | Simplified flow | When it may be considered | Main cautions |
|---|---|---|---|
| Direct compression | Dispense → sieve as needed → blend → lubricate → compress | Materials already flow, mix and compact suitably | Segregation, die fill and compactability |
| Wet granulation | Dispense → preblend → granulate → wet screen → dry → mill → final blend/lubricate → compress | Granulation can improve flow, distribution or compaction | Moisture/heat exposure and added process complexity |
| Dry granulation | Dispense → preblend → roller compact/slug → mill → final blend/lubricate → compress | Liquid exposure is unsuitable and particle engineering is needed | Compaction history, fines and tabletability |
These are families of processes. Equipment and sequence vary by manufacturer and product.
Dispensing and material control
Manufacturing begins with approved materials, specifications and batch quantities. Dispensing should preserve identity, lot traceability and reconciliation while managing allergen, cross-contamination and environmental requirements.
Before processing, confirm whether materials require de-lumping or sieving and whether that operation could alter a coated, granulated or otherwise functional ingredient. A sieve is not a universal first step; the material specification and process intent matter.
Blending and segregation risk
The goal is a blend that is sufficiently uniform and remains so through discharge, transfer and compression. Blend order, fill level, time and equipment geometry can matter.
Overmixing is not automatically safer. It can change lubricant distribution or promote segregation after an apparently uniform state. Dense and light particles, broad size distributions and low-dose ingredients require deliberate handling. Sampling should be capable of detecting the relevant risk rather than relying on one convenient location.
Granulation, drying and milling
In wet granulation, binder liquid distribution and granulation endpoint influence granule size, density and downstream behaviour. Drying must reach an appropriate state without damaging sensitive materials. Milling then controls oversize material and the distribution presented to the press.
In dry granulation, compaction pressure and milling conditions influence ribbons or slugs, fines and resulting tabletability. Reprocessing fines without a defined strategy can change the material history.
Neither route should be described only as “making the powder flow.” It creates a new intermediate whose attributes must be controlled.
Lubrication and compression
A final lubricant blend may be added shortly before compression. Its mixing time and distribution can influence ejection and tablet bonding.
The rotary press then meters material into dies, compacts it between punches and ejects the tablet. Relevant variables include feed-frame operation, press speed, fill depth, precompression, main compression, dwell time and ejection.
Operators monitor signals such as weight, thickness and mechanical strength alongside defects:
- sticking or picking;
- capping or lamination;
- edge damage;
- weight variation;
- excessive ejection force;
- visual non-uniformity.
The response should address root cause across formulation, tooling and process rather than only raising compression force.
Coating, dedusting and metal detection
Compressed cores may be dedusted before downstream handling. Metal detection may be used where appropriate to the line and risk controls.
If coating is required, tablets enter a controlled spraying and drying operation. The manufacturer must align coating composition, target weight gain, atomization and air handling with the tablet core. Coated tablets should be tested as finished units because coating can affect appearance, dimensions, stability and performance.
Quality control and release
A product-specific control strategy may include:
- raw-material identity and specifications;
- blend or granule attributes;
- in-process tablet weight, thickness and strength;
- visual defects and friability;
- disintegration and dissolution where relevant;
- assay and uniformity;
- microbiological and contaminant testing as applicable;
- packaging checks;
- stability in the market pack.
Applicable requirements depend on classification and market. A manufacturer should explain which controls are in-process, which are release tests and which are performed externally.
Packaging and line clearance
Tablets may be packed in bottles, blisters, sachets or other systems. The pack must protect the product and run on the available line. Count accuracy, seals, desiccants, induction seals, blister integrity, coding and reconciliation can all become part of production control.
Line clearance and documented changeover help prevent mix-ups. Cleaning capability should be assessed against allergens, potent ingredients, colours, flavours and other relevant residues.
Questions to ask a tablet manufacturer
Ask:
- Which process route does the formula require, and what evidence supports that choice?
- What pilot scale best represents the commercial line?
- Which tablet tooling and coating capabilities are in-house?
- How are low-dose uniformity and segregation controlled?
- Which tests are in-house, outsourced or market-specific?
- What material, tooling and packaging lead times control the schedule?
- Which process parameters and quality attributes will be reviewed at scale-up?
Pair these questions with the tablet formulation guide and tablet format guide rather than seeking a quote from a product name alone.
Sources and evidence boundaries
- Portier, Vervaet and Vanhoorne, “Continuous Twin Screw Granulation: A Review of Recent Progress and Opportunities in Formulation and Equipment Design,” Pharmaceutics 13 (2021): 668. Full text
- Peddapatla et al., “Process Model Approach to Predict Tablet Weight Variability for Direct Compression Formulations at Pilot and Production Scale,” Pharmaceutics 13 (2021): 1033. Full text
- Markl and Zeitler, “A Review of Disintegration Mechanisms and Measurement Techniques,” Pharmaceutical Research 34 (2017): 890–917. Full text
- ICH, “Q8(R2) Pharmaceutical Development.” Official guideline
This flow describes common manufacturing logic, not a master batch instruction. The approved formula, equipment, facility quality system and market requirements govern the actual process.